WorldHeart Announces Further Milestone in Miniaturized Assist Pump D... ( OAKLAND Calif. Sept. 6 /- (Nasdaq...)

WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development

Date:9/6/2007

OAKLAND, Calif., Sept. 6 /PRNewswire-FirstCall/ -- (Nasdaq: WHRT, TSX: WHT) World Heart Corporation (WorldHeart), a developer of mechanical circulatory support systems, announced successful completion of the first multi-day animal study of a miniaturized, pediatric, ventricular assist device (VAD). The PediaFlow(TM), developed by a National Institutes of Health-funded consortium including WorldHeart, is expected to be the platform for a future minimally invasive adult VAD, intended to meet a large clinical need for earlier-stage heart failure patients.

The animal implant was performed by Peter Wearden, M.D., Ph.D., pediatric cardiac surgeon at the Children's Hospital of Pittsburgh. The six-day study, at the University of Pittsburgh McGowan Institute, focused on hemodynamic performance and biocompatibility under physiologic conditions. The device provided uninterrupted support and met all design targets. Biocompatibility was demonstrated, with no indications of blood damage or clotting.

Dr. Harvey Borovetz, the Robert L. Hardesty Professor of Surgery, Chairman of Bioengineering at the University of Pittsburgh and Principal Investigator of the associated NIH PediaFlow development contract, remarked that, "With the success of the recent in vivo experiments, we are encouraged to begin 30-day animal implants, focusing again on pump performance and biocompatibility."

Mr. Jal Jassawalla, WorldHeart's President and CEO, commented, "The positive results of the initial in vivo implants highlight the potential benefits of WorldHeart's MagLev(TM) technology. We are excited that this technology, first embodied in the Levacor(TM) VAD, is being extended to the pediatric VAD and then potentially to a WorldHeart minimally invasive adult VAD." The latter, providing partial circulatory support, would serve a broad population with less advanced heart failure. Such a device would complement WorldHeart's Levacor VAD, which is intended to provide a greater degree
'/>"/>

SOURCE World Heart Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:

(Date:5/20/2008)...May 20 /- Omeros Corporatio...ment for the Phase 1 study of,OMS201, the Company,...e,for use during urological surgery. At least 24 ...al of stones with a maximum diameter of 12 mm,loca...be enrolled in the,study., "Advancing another Pha...

(Date:5/20/2008)...rial data for Perforomist(TM) (Formoterol Fumarate...tional ATS Conference --, NAPA, Calif., May 20 /P...ional Conference of the American Thoracic Society ...rforomist(TM) Inhalation Solution,(formoterol fuma...lization,and Spiriva(R) (tiotropium; TIO) is sign...

(Date:5/20/2008)...ented at the 2008 International Conference of the ...ty, TORONTO, May 20 /- For...S.A. today presented results from four clinical,tr...um bromide, an,investigational treatment for chron... four preclinical studies further describing the p...

(Date:5/20/2008)...May 20 /- GlaxoSmithKline and Synta,P...ced positive Phase II,clinical data for elesclomol...rently in development for metastatic melanoma. A r...tic melanoma patients treated with elesclomol,and ...erapy had a,statistically significant improvement ...

[0] Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study [0] Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone [0] Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD [0] Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma

...ignificant additional protection against,infection...rvical,cancer candidate vaccine, PHILADELPHIA, Jun...an interim analysis of a Phase III study show that...candidate vaccine,provides up to 100 percent prot...d by the most common types of human papillomavirus...

...tients treated with VELCADE, cyclophosphamide,and... 28, 2007 /PRNewswire-FirstCall/ -- Millennium,Pha...ion of results,from clinical trials of VELCADE bas... complete response(1) (CR) rates in previously,tre...s were,presented at the prestigious 11th Internati...

Other Medicine Technology:Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 2 Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 3 Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 4 Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 5 Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 6 Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 7 Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 2 Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 3 Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 4 Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 5 Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 6

Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma

(Date:5/20/2008)...alth care problem all over the world, with 130 mil...nt is expensive and has variable results according... land mark in treatment is the virus clearance at ...onse (ETR), but many of the patients achieving the...us, the goal of treatment is to have persistent vi...

(Date:5/20/2008)...erless prescription use yields practical guides fo...nd policy makers, WASHINGTON, MAY 20 /PRNewswire-...eHI) and the Center for Improving Medication Manag... anticipated report detailing the,impact of electr...,consumers, employers, health plans and policy mak...

(Date:5/20/2008)...APOLIS, May 20 /PRNewswire/ -- On May 25, one brig...Honda, will be racing to win,the Indianapolis 500 ...s --,Eyes on the Road. By emblazoning their car on...tp://www.eyesontheroad.org, IndyCar owners Jay Pe...s driver, IndyCar Series,veteran Tomas Scheckter o...

(Date:5/20/2008)...nhaling long, thin carbon nanotubes may result in,...ewswire-USNewswire/ -- A major study published,tod... carbon nanotubes -- a,poster child for the "nanot...bestos if inhaled in sufficient quantities., The ...types of,nanotubes have the potential to cause mes...

Breaking Medicine News(10 mins):Health News:eHealth Initiative and the Center for Improving Medication Management to Present Report Detailing Both Impact of E-Prescriptions on U.S. Health Care System and Guidelines for Achieving Optimal Results 2 Health News:eHealth Initiative and the Center for Improving Medication Management to Present Report Detailing Both Impact of E-Prescriptions on U.S. Health Care System and Guidelines for Achieving Optimal Results 3 Health News:Luczo Dragon IndyCar Carries 'Eyes on the Road' Logo to Prevent Blindness to Indy 500 2 Health News:Carbon Nanotubes That Look Like Asbestos, Behave Like Asbestos 2 Health News:Carbon Nanotubes That Look Like Asbestos, Behave Like Asbestos 3 Health News:Carbon Nanotubes That Look Like Asbestos, Behave Like Asbestos 4

[0] How to increase the chances of remaining virus free Pakistani patients with HCV?[0] eHealth Initiative and the Center for Improving Medication Management to Present Report Detailing Both Impact of E-Prescriptions on U.S. Health Care System and Guidelines for Achieving Optimal Results [0] Luczo Dragon IndyCar Carries 'Eyes on the Road' Logo to Prevent Blindness to Indy 500 [0] Carbon Nanotubes That Look Like Asbestos, Behave Like Asbestos

... study of Chinese people has linked obesity with a...population . Led by Chi C. Leung at the Tuberculo...examined 42,116 individuals aged 65 years or above... centres for elderly patients in Hong Kong. The r...

...h Sheriff Lee Baca has justified placing Paris Hil...g psychiatric condition as the reason, it seems th...the slammer was quite sure that the socialite was ..., Larry Waldie, who had informed Judge Sauer about...

...NGTON - A U.S. consumer group called for an urgent...fety of aspartame as it can be cancerous, on Mond... to do so despite a new study showing the sweetene...ished by the Italian researchers points to the fac...

...h Minister Jose Gomes Temporao plans to distribute...ew months in office, Brazils new health minister ... offerings. Brazil's government has added "morning...birth control program in hopes of helping poor peo...

Other Medicine News:Health News:Aspartame Probe Call Rejected by FDA 2 Health News:Brazil Government New Health Offer 2 Health News:Brazil Government New Health Offer 3

Obesity Linked to Lower Tuberculosis Risk in Older Chinese Population Was Paris Conning Doctors With Fake Illness?Aspartame Probe Call Rejected by FDA Brazil Government New Health Offer

The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use.

The 8600 Series Tabletop/Portable Digital Pulse Oximeter provides a simple universal tool for patient monitering. From transport applications to continuous monitoring, the 8600 has earned the confide

Halogen-free immersion oil based on ester oil.

Immersion oil composed on polyester polyol, diphenyl cresyl phosphate and tricyclodecane dimethanol.

Medicine Products:

OX-2 Pulse Oximeter 8600 series "Immersol"Immersion Oil, BTL

WorldHeart Announces Further Milestone in Miniaturized Assist Pump D...( OAKLAND Calif. Sept. 6 /- (Nasdaq...),Health